NCT03878264View on ClinicalTrials.gov

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 6, 2018

Primary Completion Date

March 24, 2019

Study Completion Date

March 24, 2019

Conditions
Healthy
Interventions
DRUG

CORT118335 Oral

CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration

DRUG

14C-CORT118335 intravenous

14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C

DRUG

14C-CORT118335 oral

14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY